Advaxis Stock Forecast, Price & News

-0.02 (-4.19 %)
(As of 07/29/2021 05:13 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.83 million shs
Average Volume11.79 million shs
Market Capitalization$60.00 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for Advaxis and its competitors with MarketBeat's FREE daily newsletter.

Advaxis logo

About Advaxis

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.34 out of 5 stars

Medical Sector

1101st out of 2,214 stocks

Pharmaceutical Preparations Industry

523rd out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Advaxis (NASDAQ:ADXS) Frequently Asked Questions

Is Advaxis a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Advaxis stock.
View analyst ratings for Advaxis
or view top-rated stocks.

What stocks does MarketBeat like better than Advaxis?

Wall Street analysts have given Advaxis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Advaxis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Advaxis?

Advaxis saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 4,420,000 shares, a decline of 23.1% from the May 31st total of 5,750,000 shares. Based on an average daily volume of 9,790,000 shares, the short-interest ratio is presently 0.5 days.
View Advaxis' Short Interest

When is Advaxis' next earnings date?

Advaxis is scheduled to release its next quarterly earnings announcement on Thursday, September 9th 2021.
View our earnings forecast for Advaxis

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) posted its earnings results on Sunday, June, 13th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The biotechnology company had revenue of $1.38 million for the quarter.
View Advaxis' earnings history

How has Advaxis' stock been impacted by Coronavirus (COVID-19)?

Advaxis' stock was trading at $0.6666 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ADXS shares have decreased by 37.4% and is now trading at $0.4171.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ADXS?

1 brokerages have issued 1-year target prices for Advaxis' stock. Their forecasts range from $2.25 to $2.25. On average, they anticipate Advaxis' stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 439.4% from the stock's current price.
View analysts' price targets for Advaxis
or view top-rated stocks among Wall Street analysts.

Who are Advaxis' key executives?

Advaxis' management team includes the following people:
  • Mr. Kenneth A. Berlin J.D., Pres, Interim CFO, CEO & Director (Age 57, Pay $1.16M)
  • Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 60, Pay $624.26k)
  • Mr. Igor Gitelman CPA, M.B.A., CPA, MBA, Chief Accounting Officer & VP of Fin. (Age 45)

Who are some of Advaxis' key competitors?

What other stocks do shareholders of Advaxis own?

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $0.42.

How much money does Advaxis make?

Advaxis has a market capitalization of $60.75 million and generates $250,000.00 in revenue each year.

How many employees does Advaxis have?

Advaxis employs 17 workers across the globe.

What is Advaxis' official website?

The official website for Advaxis is

Where are Advaxis' headquarters?

Advaxis is headquartered at 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]

This page was last updated on 7/29/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.